Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk1

2012

medicine.medical_specialtyEndocrinologyEndocrinologybusiness.industryEndocrinology Diabetes and MetabolismInternal medicinemedicinemedicine.diseasebusinessObesityGrowth hormone secretionLipoproteinClinical Endocrinology
researchProduct

Erythrocyte-associated apolipoprotein B and its relationship with clinical and subclinical atherosclerosis

2011

Eur J Clin Invest 2012; 42 (4): 365–370 Abstract Background  Apolipoprotein (apo) B-containing lipoproteins are closely linked to atherogenesis. These lipoproteins are transported in plasma and are also associated with blood leucocytes. Our aim was to investigate whether apoB-containing lipoproteins are also present on the surface of erythrocytes and investigate the relationship with the presence of atherosclerosis in a cross-sectional study. Materials and methods  Erythrocyte-bound apoB (ery-apoB) was measured by flowcytometry in subjects with (CAD+) and without coronary artery disease (CAD−), based on coronary angiography or on a history of cardiovascular disease. Intima media thickness (…

medicine.medical_specialtyEndotheliumApolipoprotein Bbiologybusiness.industryClinical BiochemistryGeneral MedicineNegative associationmedicine.diseaseLower riskBiochemistryCoronary artery diseasemedicine.anatomical_structureEndocrinologyIntima-media thicknessSubclinical atherosclerosisLipoprotein transportInternal medicinemedicinebiology.proteinlipids (amino acids peptides and proteins)businessEuropean Journal of Clinical Investigation
researchProduct

Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation

2013

Background Contrary to high-density lipoprotein (HDL) from normolipidaemic and normoglycaemic subjects, HDL from diabetic patients loses its ability to reverse the inhibition of vasorelaxation induced by oxidized low-density lipoprotein (LDL). The aim of this study was to analyze the role of glycation, a major abnormality observed in diabetes, on the impairment of the vasorelaxant effect of HDL. Methods HDL from healthy subjects was glycated in vitro by incubation in glucose 200 mmol/L for 3 days. Vasoreactivity was evaluated by the relaxation response to acetylcholine of rabbit aorta rings pre-contracted with noradrenaline, before and after 2 h incubation with or without different lipoprot…

medicine.medical_specialtyEndotheliumbusiness.industryEndocrinology Diabetes and MetabolismVasodilationmedicine.diseasechemistry.chemical_compoundEndocrinologymedicine.anatomical_structureEndocrinologyFructosaminechemistryGlycationInternal medicineDiabetes mellitusInternal Medicinemedicinelipids (amino acids peptides and proteins)businessIncubationAcetylcholinemedicine.drugLipoproteinDiabetes/Metabolism Research and Reviews
researchProduct

Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la…

2015

Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening disease characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). The Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) has recently published a clinical guide to diagnose and manage HoFH (Eur Heart J. 2014;35:2146-57). Both the Spanish Society of Atherosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF) consider this European Consensus document of great value and utility. However, there are particularities in our country which advise to ha…

medicine.medical_specialtyEzetimibeHomozygous familial hypercholesterolaemiaDiagnosisMedicinePharmacology (medical)Lipoprotein cholesterolNational healthEzetimibabusiness.industryAtherosclerotic cardiovascular diseaseDiagnósticoAféresisStatinsHipercolesterolemia familiar homocigotaLomitapidaEzetimibeLomitapidePatient managementLDL apheresisFamily medicineEuropean atherosclerosis societylipids (amino acids peptides and proteins)ApheresisCardiology and Cardiovascular MedicinebusinessEstatinasmedicine.drug
researchProduct

Diacylglycerol kinase α mediatses 17-β-estradiol-induced proliferation, motility, and anchorage-independent growth of Hec-1A endometrial cancer cell …

2011

Increased levels of endogenous and/or exogenous estrogens are one of the well known risk factors of endometrial cancer. Diacylglycerol kinases (DGKs) are a family of enzymes which phosphorylate diacylglycerol (DAG) to produce phosphatidic acid (PA), thus turning off and on DAG-mediated and PA-mediated signaling pathways, respectively. DGK α activity is stimulated by growth factors and oncogenes and is required for chemotactic, proliferative, and angiogenic signaling in vitro. Herein, using either specific siRNAs or the pharmacological inhibitor R59949, we demonstrate that DGK α activity is required for 17-β-estradiol (E2)-induced proliferation, motility, and anchorage-independent growth of …

medicine.medical_specialtyGPR30medicine.drug_classCell SurvivalDiacylglycerol kinaseMotilityEstrogen receptorEnzyme AssayEndometrial carcinomaBiologyQuinazolinoneReceptors G-Protein-CoupledPiperidinePiperidinesCell MovementInternal medicineCell Line TumormedicineCell AdhesionHumansEndometrial NeoplasmEnzyme AssaysQuinazolinonesDiacylglycerol kinaseCell ProliferationEstradiolCell growthKinaseCell BiologyDiacylglycerol kinase; Endometrial carcinoma; Estrogen; GPR30; Cell BiologyEstrogenEndometrial NeoplasmsCell biologyEnzyme ActivationLipoprotein LipaseEndocrinologyReceptors EstrogenEstrogenGene Knockdown TechniquesGene Knockdown TechniqueFemaleRNA InterferenceSignal transductionGPERHuman
researchProduct

How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks fo…

2020

Familial hypercholesterolemia (FH) is a common genetic disorder of lipid metabolism, still underdiagnosed and undertreated in the general population. Pathology registers could play a crucial role in the creation of a comprehensive and integrated global approach to cover all aspects of this disease. Systematic data collection of patients affected by FH has increased dramatically worldwide in the past few years. Moreover, results from registers already established for the longest time showed their potentialities in the implementation of the knowledge of FH, comparing country-specific approaches and providing real-world data about identification, management and treatment of FH individuals in t…

medicine.medical_specialtyGenotypeFamilial hypercholesterolemiaPopulationFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineGenetic dyslipidaemiasFamilial hypercholesterolemia; Genetic dyslipidaemias; Pathology registersInternal MedicineHumansMedicineGenetic Predisposition to DiseaseRegistries030212 general & internal medicineeducationIntensive care medicineHypolipidemic Agentseducation.field_of_studybusiness.industryGenetic disorderDiagnostic algorithmsGeneral MedicinePathology registersmedicine.diseaseClinical PracticePhenotypeItalyCardiovascular DiseasesHeart Disease Risk FactorsDisease riskIdentification (biology)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAlgorithmsAtherosclerosis Supplements
researchProduct

Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits.

1998

Abstract —Low-density lipoprotein (LDL) can be transformed to an atherogenic moiety by nonoxidative, enzymatic degradation. Enzymatically degraded LDL induces macrophage foam cell formation, provokes release of cytokines, and also activates complement. To determine whether complement activation may contribute to atherogenesis, 6 pairs of homozygous C6-deficient rabbits and their non–C6-deficient heterozygous siblings were fed a cholesterol-rich diet for 14 weeks. Cholesterol levels and plasma lipoprotein profiles of the animals in the C6-competent and C6-deficient groups did not significantly differ, and the high density lipoprotein and LDL cholesterol ratios at the end of the experiment w…

medicine.medical_specialtyHeterozygoteArteriosclerosisBiologyPathogenesisCholesterol Dietarychemistry.chemical_compoundHigh-density lipoproteinInternal medicinemedicine.arterymedicineMacrophageAnimalsComplement ActivationFoam cellAortaCholesterolHomozygoteComplement systemComplement C6EndocrinologychemistryImmunologyDiet AtherogenicRabbitsCardiology and Cardiovascular MedicineLipoproteinArteriosclerosis, thrombosis, and vascular biology
researchProduct

Identification of a novel mutation of MTP gene in a patient with abetalipoproteinemia.

2011

Abetalipoproteinemia (ABL), or Bassen-Kornzweig syndrome, is a rare autosomal recessive disorder of lipoprotein metabolism, characterized by fat malabsorption, hypocholesterolemia retinitis pigmentosa, progressive neuropathy and acanthocytosis from early infancy. We describe the clinical and molecular characterization of a 6-month-old infant born of consanguineous, apparently healthy parents from Iran. The patient was hospitalized because of failure to thrive, greasy stool and vomiting. The patient's serum lipid profile, the clinical phenotype and the duodenal histology suggested the clinical diagnosis of ABL. The MTP gene analysis by direct sequencing revealed a novel homozygous mutation (…

medicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaDuodenumSpecialties of internal medicineInternal medicineRetinitis pigmentosamedicineHumansgeneticsFamily HealthMTP gene mutations.ABLHepatologymedicine.diagnostic_testApoB-containing lipoproteins.business.industryAbetalipoproteinemiaInfantAbetalipoproteinemia.Heterozygote advantageGeneral Medicinemedicine.diseaseLipidsAbetalipoproteinemiaFat malabsorptionHypocholesterolemiaEndocrinologyPhenotypeRC581-951Failure to thriveFemaleHypocholesterolemia.medicine.symptomLipid profilebusinessCarrier Proteins
researchProduct

The effect of oral hormone replacement therapy on lipoprotein profile, resistance of LDL to oxidation and LDL particle size

2001

Abstract Objectives: To disclose if oral estradiol (E 2 ), alone or in combination with natural progesterone (P) or medroxyprogesterone acetate (MPA), may modify the oxidizability of low density lipoprotein (LDL), and if the effect is achieved at physiological dosages. LDL oxidizability was assessed by the resistance to oxidation by copper and by the particle size profile, since small particles have increased oxidation susceptibility. Methods: Thirty-three women received two consecutive, two-month length doses of 1 and 2 mg/day of oral E 2 . They were then randomly assigned to a fourteen-day treatment of 2 mg/day E 2 plus either 300 mg/day P or 5 mg/day MPA. A parallel group of experiments …

medicine.medical_specialtyHormone Replacement Therapymedicine.drug_classMedroxyprogesteroneAdministration OralMedroxyprogesterone AcetateGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundHigh-density lipoproteinOral administrationInternal medicinemedicineHumansMedroxyprogesterone acetateParticle SizeProgesteroneDiminutionDose-Response Relationship DrugEstradiolbusiness.industryObstetrics and GynecologyCholesterol LDLMiddle AgedPostmenopauseEndocrinologychemistryEstrogenLow-density lipoproteinFemalelipids (amino acids peptides and proteins)businessOxidation-Reductionmedicine.drugLipoproteinMaturitas
researchProduct

Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?

2019

Abstract Background Although lipid-lowering drugs, especially statins, and recently also PCSK9 inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (CVD) including coronary artery disease (CAD) events most efficiently, only 5–10% of high-risk cardiovascular patients reach the target values recommended by international guidelines. In patients who cannot be treated adequately by drugs it is possible to reduce increased LDL-C and/or lipoprotein(a) (Lp(a)) values by the use of lipoprotein apheresis (LA) with the potential to decrease severe CVD events in the range of 70%->80%. Even in Germany, a country with well-established reimbursement guidelines for…

medicine.medical_specialtyHyperlipoproteinemiasReferralPopulationDisease030204 cardiovascular system & hematologyRisk AssessmentHealth Services AccessibilityCoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal MedicinemedicineHumans030212 general & internal medicineIntensive care medicineeducationCompetence (human resources)Reimbursementeducation.field_of_studybusiness.industryPatient SelectionGeneral MedicineCholesterol LDLmedicine.diseaseCardiovascular DiseasesBlood Component RemovalPatient ComplianceLipid loweringCardiology and Cardiovascular MedicinebusinessLipoprotein apheresisBiomarkersLipoprotein(a)Atherosclerosis. Supplements
researchProduct